- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Wall Street JournalEN
R
RGEN
Repligen
126.09
-1.43-1.12%After Hours: 126.09 0.00 0.00%16:10 06/16 EDT
OPEN/PREV CLOSE127.72/127.52
TODAY RANGE120.68-127.72
VOL1.09M
MARKET CAP7.08B
52 WEEK RANGE102.97-182.52
AVG VOL (3M)831.21K
% TURNOVER1.95%
TURNOVER--
P/E (TTM)-277.7313
% RANGE5.52%
EPS(TTM)-0.4540
P/E(FORWARD)159.61
P/B3.568
BVPS35.34
DIVIDEND--
P/S11.15
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP6.61B
SHARES OUTSTANDING56.18M
NEXT EARNINGS07/28-08/01
FREE FLOAT52.45M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Benzinga·10h ago
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Seeking Alpha·06/08 16:12
Repligen: Long-Term Growth Gem Suffers Some Setbacks
TipRanks·06/03 13:15
Craig-Hallum Sticks to Its Buy Rating for Repligen (RGEN)
TipRanks·05/30 12:17
Regeneron Stock (REGN) Retreats as Lung Disease Drug Data Disappoints
Seeking Alpha·05/28 13:30
Baird Small/Mid Cap Growth Equity Fund Q1 2025 Commentary
Seeking Alpha·05/26 17:59
BNY Mellon Small/Mid Cap Growth Fund Q1 2025 Commentary
NASDAQ·05/22 10:58
The Math Shows MDY Can Go To $634
TipRanks·05/15 21:13
Repligen Holds Annual Shareholders Meeting, Key Decisions Made
Benzinga·04/30 21:01
Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings)
Dow Jones·04/30 16:16
Repligen Price Target Cut to $189.00/Share From $202.00 by RBC Capital
Dow Jones·04/30 16:16
Repligen Is Maintained at Outperform by RBC Capital
Benzinga·04/30 16:06
RBC Capital Maintains Outperform on Repligen, Lowers Price Target to $189
Same Industry
Name/Symbol
Change%
Price